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Abstract
A 32 yr old woman came to the hospital with a history of treatment for primary
amenorrhea once in 2007. Diagnosis of Kallmann syndrome was made based on
her complaint of amenorrhea and anosmia. Physical examination revealed abnormal
growth of secondary sexual characteristic including undeveloped breasts, lack of
armpit and pubic hair. The external genitalia examination showed very slightly
pubic hair, a small labia minora, and vagina (± 0.5 cm diameter, 5 cm depth). The
abdominal ultrasound examination showed a small uterus. Bone marrow densitometry
examination denoted osteoporosis in L1, L2, L3, L4 vertebrae and pelvic bone.
Chromosomal examination showed the karyotype of 46 XX. The olfactory test resulted
in anosmia. Kallmann syndrome is a developmental disorder which consists of a
combination of hypogonadotropic-hypogonadism and anosmia. The characteristics of
patients diagnosed with Kallmann syndrome were delayed puberty and anosmia. A
chromosomal and hormonal examination might be performed to rule out Klinefelter
and Turner syndrome. Magnetic Resonance Imaging (MRI) examination was useful to
determine whether there was any olfactory bulb or pituitary gland and hypothalamus
disorder. Patient’s management included hormone replacement therapy and fertility
therapy to maintain healthy hormone circulation equal to a normal physiological
value according to patients’ ages. In this case, the effect of the drugs was to build a
temporary endometrial wall. Once the pills are stopped, the patient will not undergo
her menstruation phase anymore because of her pituitary hormone production is
inadequate. This medication also gave more strength to bones due to her osteoporosis.
Keywords: Amenorrhea, Anosmia, Genetic disorder, Hypogonadism-
hypogonadotropic, Kallmann syndrome.
1. Introduction
Kallmann Syndrome is a developmental disorder combined with hypogonadotropic-
hypogonadism and anosmia or hyposmia, where the individual’s olfactory function is
decreased [1]. This anosmia or hyposmia is related to the lack of bulb or olfactory tract
hypoplasia. This hypogonadism is caused by a deficiency of gonadotropin-releasing
hormone (GnRH) and is a result of the failure of synthetic embryonic migration of
gonadotropin-releasing hormone neurons to the forebrain [2, 3].
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The correlation between anosmia and reproduction system disorder was first pre-
sented by a Spanish pathologist named Maestre de San Juan in 1856. He did not dis-
cover any olfactory bulb in male cadavers who had anosmia in their lives. A geneticist
from America in 1944 named Franz Josef Kallmann published a study related to the
genetic explanation on the condition of patients with sexual immaturity and anosmia
and presented it as a syndrome. This syndrome is defined as a combination of signs and
symptomswhich can cause certain diseases. Afterward, the syndrome is called Kallmann
Syndrome [3, 4]
The terminology used to describe cases with Hypogonadotropic-Hypogonadism (HH)
may vary. The term Congenital Hypogonadotropic-Hypogonadism (CHH) is often used
today. Other terms which can be used are Idiopathic Hypogonadotropic-Hypogonadism
(IHH), normosmic Hypogonadotropic-Hypogonadism (nHH) or hypothalamic hypogo-
nadism. The term HH can be used for all cases, including Kallmann syndrome [6].
The term hypogonadism describes a low amount of sex hormone circulation; testos-
terone in men and estrogen and progesterone in women. Hypogonadism could hap-
pen in some different methods. The use of the term hypogonadotropic is related to
hypogonadism discovered in HH which is caused by a disorder of the production of
gonadotropin hormones which are released by the anterior pituitary gland, which are
Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) [5, 6].
LH and FSH have direct roles in women’s ovaries and men’s testes. The lack of LH and
FSH means early puberty that cannot start at the right time and eventually ovaries and
testes were not managed to show normal fertility functions, which are the maturation
and release of egg cells in women and sperm production in men [2– 4]. The underlying
cause of the failure to produce LH and FSH is some disorders in the hypothalamus
to release GnRH hormone which in normal condition stimulate the productions of LH
and FSH. Without normal release of GnRH, pituitary gland cannot release LH and FSH,
causing disorder in ovaries and testes to function normally [3, 5]. Hypogonadotropic-
Hypogonadism could happen in an isolated condition which can be influenced by LH
and FSH only or combination of pituitary deficiency condition as in CHARGE syndrome
[7].
There are 16 genetic defects which have been described as causes of Kallmann
syndrome or other forms of HH which cause disorder of GnRH production. The genes
are inherited and no one with the gene defects which shows in general for all cases
through the genetic test and this inheritance prediction is still debated [8]
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Kallmann Syndrome is a rare disorder. The number of incidences in men is 1:10 000
and in women 1:70 000. This case report describes Kallmann syndrome in a female
patient who sought treatment in Dr. Sardjito General Hospital in early 2014.
2. Case Report
A woman, 32 yr old, P0A0, came to Dr. Sardjito General Hospital with a complaint that
she never had menstruation. The patient previously went to an obstetrician and gyne-
cologist in Bumiayu (2007) and was diagnosed with hormonal deficiency and received
Yasmin and Angelique pills therapy for 3 mo. The patient said there was dark red men-
strual blood for 5 d. After that, there was no more menstrual blood. After consuming the
medicines, the patient said her breasts became firm, and a few pubic hairs started to
grow in public area. Aside from nomenstruation, the patient complained that her breasts
had not grown, and she did not have hair in her armpits and pubis. Another complaint
from the patient is she cannot smell any scent no matter how sharp. The patient is the
11𝑡ℎ child of 11 siblings, and the patient said no other sibling has her disorder.
The family history of high blood pressure, diabetes, asthma, heart disease, and allergy
of drugs is denied. There was no history of vaginal discharge, no history of menstruation
(except when she was 20 and after taking Yasmin and Angelique medicines). She had
never been married and never had any sexual intercourse.
Based on physical examination in Dr. Sardjito General Hospital, it was discovered
that her blood pressure was 110/70 mm Hg, pulse 86 times/min, respiration rate was 20
times/min, temperature 36.7 ∘C, weight 55 kg, and height 165 cm. The general condi-
tion was good, conscious, and not anemic. Examination of signs of secondary sexual
growth showed undeveloped breasts with no armpit hair and very thin pubic hair. Chest
and abdominal examination were within normal limit. Examination of external genitalia
showed very thin pubic hair, a small labia majus and minus, clitoris and external ure-
thral opening within normal limit. There is vestibulum of the vagina, perineal body, and
mini vagina with approximately 0.5 cm diameter and 5 cm depth of sondage. A rectal
examination discovered that anal sphincter muscle tonus was normal, slippery anorectal
mucosa, a small uterus sized approximately (3 × 2 × 1) cm3, and a normal parametrium.
From the laboratory finding, the normal result was found in the routine blood exam-
ination. Hormonal examination result showed FSH 0.40 mIU ⋅ mL−1, Estradiol < 10.00
pg ⋅ mL−1, TSH 2.105 μIU ⋅ mL−1, and Prolactin 3.20 ng ⋅ mL−1. During ultrasonography
examination, the bladder was normal, uterus sized (4 × 1.5 × 1) cm3 was seen, and no
other tumor mass was discovered. Bonemarrow densitometry examination for L1, L2, L3,
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Figure 1: Patient’s breasts became firm after first hormonal therapy.
Figure 2: Patient’s mini vagina.
L4 vertebrae and pelvic bone showed osteoporosis. Chromosomal examination showed
46, XX karyotype and the conclusionwere female genotype. This patient also underwent
the olfactory test and was diagnosed with anosmia.
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Based on anamnesis and all of the examination, Kallmann syndrome diagnosis was
given. One cycle of hormone replacement therapy with Angelique (estradiol 1 mg and
drospirenone 2 mg) and Estero pills on 1 d to 21 d, the combination with Prothyra pills on
11 d to 21 d.
3. Discussion
Kallmann syndrome is a developmental disorder which consists of a combination of
hypogonadotropic-hypogonadism and anosmia. The characteristics or clinical descrip-
tions of Kallmann syndrome and hypogonadotropic-hypogonadism can be separated
into two categories. It is not only reproductive, such as failure to start or reach complete
puberty in men as well as women; primary amenorrhea or failure of first menstruation
in women; poor growth of secondary sexual characteristics and infertility; but also non-
reproductive such as hypogonadotropic-hypogonadism; anosmia or hyposmia; cranio-
facial defects; unilateral agenesis or aplasia; defects in hearing nerves and teeth and
synkinesis [1, 4, 9].
Not all symptoms will appear in every case of Kallmann syndrome/HH. It also does not
happen to all family members. Several clinical descriptions are associated with genetic
defects which are known to cause Kallmann syndrome/HH, however in several cases it is
unknown why clinical descriptions of Kallmann syndrome appear. Similarly, in this case,
all reproductive clinical descriptions including failure to start or reach complete puberty,
primary amenorrhea, obstructed growth of secondary sexual characteristic and infer-
tility were discovered. The discovered non-reproductive clinical descriptions included;
hypogonadotropic-hypogonadism, congenital, anosmia, synkinesis, dental defect and
increased height due to lateness of treatment. The cause of her Kallmann syndrome
also not related to genetic disorder because based on her chromosomal examination,
there is no genetic disorder. None of the patient’s siblings has Kallmann syndrome like
her. This could happen due to HCG which is produced by placenta in 12 wk to 20 wk
of pregnancy is normally not influenced by Kallmann syndrome or HH, so nearly all
patients with Kallmann syndrome and other forms of HH are born with normal sexual
differentiation, physically male or female [10].
3.1. Diagnosis
Kallmann syndrome diagnosis is often made when searching for the cause of delayed
puberty. One of the difficulties in diagnosing Kallmann syndrome and other forms of
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HH is the ability to differentiate normal delayed puberty from Kallmann syndrome or
hypogonadotropic-hypogonadism [1, 4].
Main biochemical parameters in men are low testosterone serum and low
gonadotropin, LH, and FSH values and in women low estrogen serum and low LH
and FSH values. In this case, laboratory examination results were 0.40 mIU ⋅ mL−1 FSH,
< 10.00 pg ⋅ mL−1 Estradiol which was lower than normal parameter.
In women and men with delayed puberty, puberty can start naturally without ther-
apy. However, delayed therapy in cases of Kallmann syndrome/HH will cause delayed
physical growth of patients and several psychological problems [4, 5]. In women, some-
times diagnosis was late because normal amenorrhea is investigated before Kallmann
syndrome/HH is considered. In this case, Kallmann syndrome is established when the
patient was 32 yr old because the patient had only sought treatment in Dr. Sardjito
General Hospital in early 2014.
The overall endocrine examination was offered to count pituitary hormones, espe-
cially prolactin to check whether pituitary gland worked correctly. In this case, the
patient’s prolactin was 3.20 ng ⋅mL−1, and this is within normal range which means that
the pituitary gland worked correctly. General medical examination such as overweight
or underweight due to chronic or acute diseases can cause delayed puberty. It is vital for
the patients to get a complete endocrine examination to differentiate between Kallmann
syndrome/HH and other cases with delayed puberty [1, 5, 12].
Bone age can be determined by X-ray examination on hand and wrist bones. If bone
age is lower than the patient’s age, it can be concluded as delayed puberty. BMD exami-
nation can also be performed to determine bone age, usually to spines and pelvic bones.
In this case, the patient underwent BMD examination on L1, L2, L3, L4 vertebrae, pelvic
bone, and was diagnosed with osteoporosis.
Chromosome examination can be performed to rule out Klinefelter syndrome and
Turner syndrome, although hormonal examination can eliminate those disorders. In this
case, chromosome examination was performed and showed karyotype 46, XX and the
conclusion was female genotype.
Magnetic resonance imaging (MRI) examination can be used to determine whether
there is any olfactory bulb and disorder in pituitary gland and hypothalamus [2, 7]. Stan-
dard olfactory examination can be used to check anosmia.
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3.2. Pathophysiology
Kallmann syndrome and other forms of hypogonadotropic-hypogonadism (HH) can be
categorized into pituitary and endocrine disorders. The results were puberty failure
and development of secondary sexual characteristics, the cause of these disorders is
between the locations of two endocrine glands in the brain [1, 4, 5].
Hypothalamus and pituitary glands control all hormonal activities in the body. The
glands secret certain amounts of various hormones with varying effects on the body.
Kallmann syndrome/Hypogonadotropic-hypogonadism is produced by a communica-
tion problem between hypothalamus and pituitary on a set of hormones. Other actions
of hypothalamus and pituitary glands are unaffected [1, 4, 5]. Usually, the hypothalamus
releases gonadotropin-releasing hormone (GnRH). GnRH is released from hypothala-
mus all day long through the hypophyseal portal system and reacts with anterior pitu-
itary glands, causing it to release to hormones called gonadotropin. The hormones
are luteinizing hormone (LH) and stimulating follicle hormone (FSH) which have direct
actions on testes for men and ovaries for women. LH and FSH are essential to stimulate
the development of secondary sexual characteristics which can be seen during puberty
and to maintain normal values of sex steroid such as testosterone in men and estrogen
and progesterone in women [4, 5, 8, 9]. In Kallmann syndrome/HH, the release of GnRH
is blocked or severely lacking. GnRH is released from hypothalamus by special neural
cells or neurons. In the tenth weeks of brain development, GnRH neurons migrate from
the source to hypothalamus [4, 5, 8].
GnRH neurons come from brain development area called olfactory placode; the neu-
rons then pass cribriform plate and the structure is called olfactory bulb, where smelling
sensations are originated from. From there the neurons migrate to the hypothalamus.
If there is any problem with the development of the olfactory bulb, the progress of
GnRH neurons can be blocked. If GnRH neurons cannot reach hypothalamus, there’s no
GnRH, causing declines of FSH and LHwhich caused failure of puberty and deficiency of
testosterone in men and estrogen and progesterone in women. In Kallmann syndrome,
there is no olfactory bulb, or it is not entirely developed, causing total olfactory sensation
disorder (anosmia) or severely deficient olfactory sensation (hyposmia). Other forms
of HH have normal development of olfactory bulb, so there’s no olfactory sensation
disorder, but GnRH neuronmigration is influenced elsewhere and prevented the release
of GnRH at the right time [2, 7, 11].
Most genes related to Kallmann syndrome/HH play roles in generation, migration or
activities of GnRH neurons and have the abilities to stimulate the productions of LH and
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FSH. Genetic relationship in Kallmann syndrome and other forms of HH is still unclear
so far with around 70 % cases with an unknown cause. In this case, the patient has no
genetic anomaly because chromosomal examination showed normal result [4, 12, 13].
Phenotype spectrum of Kallmann syndrome/HH includes classical hypogonadotropic-
hypogonadism, adult-onset hypogonadotropic-hypogonadism, reversible Kallmann syn-
drome/HH, hypothalamic amenorrhea, and normal puberty without reproductive symp-
toms.
3.3. Therapy
The purposes of hypogonadism therapies in Kallmann syndrome are firstly to start vir-
ilization or breast development and secondly for fertility development. Therapies in
Kallmann syndrome and other forms of hypogonadotropic-hypogonadism (HH) can be
categorized into hormone replacement therapy and fertility therapy [1–3, 8].
The purpose of hormone replacement therapy (HRT) in men andwomen is tomaintain
normal hormone circulation (testosterone in men and estrogen/progesterone in women)
equal to the normal physiological value in accordance to patients’ ages. After optimal
physical development is achieved with HRT administration, in men it is continued by
maintaining normal androgynous functions such as libido, muscle development, energy
level, hair growth, and sexual functions. In women, various types of HRT are adminis-
trated for the menstrual cycle. HRT is very important for men and women to maintain
bone density and reduce risks of early onset of osteoporosis.
Human chorionic gonadotropin (HCG) is sometimes used to stimulate testosterone
production in men and induction of ovulation in women. Human menopausal
gonadotropin (hMG) is used to stimulate sperm production in men and double egg
production and induction of ovulation in women.
Fertility therapy includes administering gonadotropin LH and FSH to stimulate the
production and release of eggs and sperms. Women with Kallmann syndrome or HH
have advantages over men if the normal ovaries contain normal number of eggs and
sometimes it takes a few weeks of therapy to reach fertility, while in men therapy can
last up to 2 yr to reach fertility.
In this case, the patient was given one cycle of hormone replacement therapy with
Angelique (estradiol 1 mg and drospirenone 2mg) and Estero pills on 1 d to 21 d, the com-
bination with Prothyra pills on 11 d to 21 d. The result of these treatments was the patient
was finally able to have her first menstruation after the administration of the drugs. The
effects of the drugs were to build her endometrial wall but only for a temporary moment.
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Once the pills are stopped, the patient will not undergo hermenstruation phase anymore
because of the hormone production of her pituitary gland is inadequate. This medication
also gave more strength to her bones due to her osteoporosis condition.
4. Conclusions
Kallmann syndrome is a developmental disorder combined with hypogonadotropic-
hypogonadism and anosmia or hyposmia which is lack of or reduced olfactory. This
hypogonadism is caused by gonadotropin-releasing hormone (GnRH) deficiency and
is the result of the failure of synthetic embryonic migration of gonadotropin-releasing
hormone neurons to the forebrain. Kallmann syndrome diagnosis, in this case, is based
on anamnesis of amenorrhea and anosmia, a physical examination which did not
discover secondary sexual characteristic growth including undeveloped breasts, lack
of armpit hair, and lack of pubic hair. Supporting examination showed a decline of
gonadotropin hormone, USG showed uterine hypoplasia, BMD showed osteoporosis,
and chromosomal examination showed the normal result. Patient’s therapy, in this case,
included hormone replacement therapy and fertility therapy. Hormone replacement
therapy is used to prevent her from severe osteoporosis while the fertility therapy
is given to influence her periods. Due to her small uterus and mini vagina, we still
have to face other problems such as difficulty in sexual activities and the possibility of
pregnancy.
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